TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04462523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone
Description: Standard of care topical drop treatment
Study: NCT02054910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Block
Description: Patients will receive celiac plexus block during endoscopy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will not receive celiac plexus block during endoscopy.
Study: NCT02201095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced air warming

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conduction warming mattress
Study: NCT02998476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib once daily for 8 weeks followed by once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib once daily for 8 weeks followed by once weekly
Study: NCT04303754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes-Specific Formula
Description: Other: Diabetes Specific Formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread with Spread
Description: Other: White Bread with Spread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice Porridge
Description: Other: Rice Porridge
Study: NCT02945371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered inhibitory control training
Description: A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active behavioral response training
Description: A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
Study: NCT00985959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26866138 0.7 mg/m2
Description: JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26866138 1.0 mg/m2
Description: JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26866138 1.3 mg/m2
Description: Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26866138 1.3 mg/m2
Description: Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Study: NCT03383809

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry juice with Inulin
Description: Mixture of polyphenols and non digestible carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry Juice
Description: Source of Polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Source of non digestible carbohydrate
Study: NCT03331432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid
Description: Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking daily placebo capsules for 4 weeks.
Study: NCT01659047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1101
Description: 150 mg taken twice daily by mouth
Study: NCT00748488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy aimed to move safely
Description: Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy aimed to improve Physical Activity
Description: Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
Study: NCT00985959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Study: NCT04310176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/m2 as 20-to-30 minute intravenous (i.v.) infusion every two weeks. Maintenance treatment (both arms): 5 mg/m2 every 2 weeks (in combination with 5-Fluorouracil) or 7.5 mg/m2 every 3 weeks (in combination with capecitabine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/m2 as 20-to-30 minute intravenous (i.v.) infusion every two weeks. Maintenance treatment (both arms): 5 mg/m2 every 2 weeks (in combination with 5-Fluorouracil) or 7.5 mg/m2 every 3 weeks (in combination with capecitabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 regimen
Description: Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mOXXEL regimen
Description: Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mOXXEL regimen
Description: Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: given orally from 500mg-1500mg daily and an intra-patient titration for a target serum level of 50-100µg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Maintenance treatment (both arms): Levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Maintenance treatment (both arms): Levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two weeks
Study: NCT05091554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoral ice pack application
Description: Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoral ice pack application
Description: Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoral ice pack application
Description: Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoral ice pack application
Description: Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.
Study: NCT03579433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORA with VerifEye+
Description: Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Barrett Toric Calculator
Description: Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrysof® IQ Toric IOL
Description: Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof® IQ Toric IOL
Description: Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
Study: NCT04041024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tasks and questionnaires
Description: Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer.

Intervention type: OTHER
Group type: OTHER
Intervention: tasks and questionnaires
Description: Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer.
Study: NCT00437619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcipotriol hydrate [Daivonex]
Description: 50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
Study: NCT04665349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia Pre-op, 400 milliliters, per os
Description: After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
Study: NCT04355052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine in combination with camostat mesylate
Description: Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine in combination of Azithromycin
Description: Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
Study: NCT02672137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: knowledge translation
Description: knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
Study: NCT03083093

Intervention type: DIAGNOSTIC_TEST
Intervention: The initial CTPA will be reviewed
Description: The initial CTPA will be reviewed

Intervention type: DIAGNOSTIC_TEST
Intervention: The initial CTPA will be reviewed
Description: The initial CTPA will be reviewed
Study: NCT01591655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: 1 drop of study medication into the study eye four times daily (QID) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop of vehicle into the study eye QID for 14 days.
Study: NCT02864147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine
Description: All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
Study: NCT03289416

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pure PRP II
Description: The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PureBMC
Description: The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
Study: NCT01170923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDR-PET
Description: FDR-PET performed after 1 cycle of chemotherapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: CT performed after 3 cycles of chemotherapy
Study: NCT02671864

Intervention type: OTHER
Group type: OTHER
Intervention: 1: incretin-based therapy

Intervention type: OTHER
Group type: OTHER
Intervention: 2: other antidiabetic
Study: NCT03045302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIM23B065
Description: Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
Study: NCT04219917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
Study: NCT01395914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin HCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02251197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIII 890 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02517125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral robotic-assisted surgery with Da Vinci Xi
Study: NCT02920021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Humanized monoclonal antibody, administered by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion
Study: NCT04300452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Administration of Carbetocin after placental detachment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergometrine Maleate
Description: Administration of ergometrin after placental detachment
Study: NCT05143008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Intervention
Description: Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
Study: NCT04208321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
Study: NCT02863913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
Study: NCT01673100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion Intervention
Description: Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
Study: NCT03053635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLD1433 infusion and photodynamic therapy (PDT) treatment
Description: TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).